UL10 |
Y |
Putative membrane glycoprotein. Immunosuppressive, Impairs T cell function (Bruno et al., 2016) |
UL11 |
Y |
Membrane glycoprotein. Modulates T cell signalling/function (Gabaev et al., 2014; Arcangeletti et al., 2015) |
UL13 |
|
Unknown function |
UL4 |
Y |
Putative membrane glycoprotein (Van Damme and Van Loock, 2014) |
UL5 |
|
Putative membrane glycoprotein (Van Damme and Van Loock, 2014) |
UL6 |
Y |
Putative membrane glycoprotein (Van Damme and Van Loock, 2014) |
UL7 |
Y |
Membrane glycoprotein. Modulates chemo- and/or cytokine-signalling function (Pérez-Carmona et al., 2018) |
UL8 |
Y |
Transmembrane glycoprotein. Inhibits proinflammatory cytokines (Pérez-Carmona et al., 2018) |
US26 |
|
Unknown function |
US27 |
Y |
Membrane glycoprotein. Activates CXCR4 signalling to increase human cytomegalovirus replication (Frank et al., 2019) |
UL150A |
|
Fibroblast and epithelial cell entry (Houldcroft et al., 2016) |
UL2 |
|
Putative membrane glycoprotein (Van Damme and Van Loock, 2014) |
RL11 |
Y |
Membrane glycoprotein. Binds IgG Fc domain involved in immune regulation (Van Damme and Van Loock, 2014) |
UL147 |
|
α-Chemokine homologue (Katoh and Standley, 2013; Paradis and Schliep, 2019) |
UL40 |
|
Control of NK recognition (Heatley et al., 2013) |
RL13 |
Y |
Glycoprotein, repression of replication, binds IgG domain immune regulation (Stanton et al., 2010; Cortese et al., 2012) |
RL10 |
|
Membrane glycoprotein |
UL57 |
|
Ss DNA binding protein (Van Damme and Van Loock, 2014) |
UL50 |
|
Nuclear Egress complex. Reduces interferon-mediated antiviral effect (DeRussy et al., 2016) |